Confo Therapeutics receives €1.7 million grant from VLAIO to progress novel GPCR-modulating compounds for an orphan indication

21. June 2019

|In Portfolio News

|By eazee-designstudio

Confo Therapeutics today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will run over two years and will support one of the Company’s proprietary pre-clinical programs, targeting a neurological orphan indication. The grant will also support translational biology work by Confo alongside the teams of Prof Patrik Verstreken (VIB-KU Leuven Center for Brain & Disease Research), Prof Peter de Witte (Molecular Biodiscovery, KU Leuven) and Prof Guy Bormans (Radiopharmaceutical Research, KU Leuven).